Shahrzad Arya

Shahrzad Arya

Auto-generated profile, based on publicly available information

Shahrzad Arya

Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
Marco VentinMarco Ventin
Marco Ventin
GCGiulia Cattaneo
Giulia Cattaneo
SAShahrzad Arya
Shahrzad Arya
JJJingyu Jia
Jingyu Jia
MGMaria Chiara Gelmi
Maria Chiara Gelmi
CFCristina R. Ferrone
Cristina R. Ferrone
Purpose: Uveal melanoma (UM) is the most common intraocular malignant tumor. Despite successful treatment of the primary tumor, about 50% of patients will recur with systemic diseases for which there are no effective treatment strategies. Here we investigated the preclinical efficacy of a chimeric antigen receptor (CAR) T-cell–based immunotherapy targeting B7-H3. Experimental Design: B7-H3 expression on primary and metastatic human UM samples and cell lines was assessed by RNA sequencing, flow cytometry, and immunohistochemistry. Antitumor activity of CAR T cells targeting B7-H3 was tested in vitro with UM cell lines, patient-derived organotypic tumor spheroids from patients with metastatic UM, and in immunodeficient and humanized murine models. Results: B7-H3 is expressed at high levels in >95% UM tumor cells in vitro and in vivo. We generated a B7-H3 CAR with an inducible caspase-9 (iCas9) suicide gene controlled by the chemical inducer of dimerization AP1903, which effectively kills UM cells in vitro and eradicates UM liver metastases in murine models. Delivery of iCas9.B7-H3 CAR T cells in experimental models of UM liver metastases demonstrates a durable antitumor response, even upon tumor rechallenge or in the presence of a significant metastatic disease burden. We demonstrate effective iCas9.B7-H3 CAR T-cell elimination in vitro and in vivo in response to AP1903. Our studies demonstrate more effective tumor suppression with iCas9.B7-H3 CAR T cells as compared to a B7-H3-targeted humanized monoclonal antibody. Conclusions: These studies support a phase I clinical trial with iCas9.B7-H3 CAR T cells to treat patients with metastatic UM.

11 December 2025 in Annals of Surgery
Verified
Journal Article
Closed access
SAShahrzad Arya
Shahrzad Arya
MVMarco Ventin
Marco Ventin
LZLiti Zhang
Liti Zhang
CCCarlos Fernandez-Del Castillo
Carlos Fernandez-Del Castillo
AGAlexandra Gangi
Alexandra Gangi
CFCristina R. Ferrone
Cristina R. Ferrone
Objective: To compare the short- and long-term outcomes of the Warshaw (splenic vessel resection) and Kimura (splenic vessel preservation) techniques in spleen-preserving distal pancreatectomy (SPDP). Summary Background Data: SPDP is an alternative to splenectomy that preserves immune function. Both Warshaw and Kimura are used, but comparative data on their long-term safety and indications are limited. Methods: Retrospective bi-institutional analysis of 297 patients undergoing SPDP at Massachusetts General Hospital and Cedars-Sinai Medical Center (2002–2020). Clinicopathologic, operative, and radiologic outcomes were compared. Results: Of 297 patients, 245 (82.5%) underwent Warshaw and 52 (17.5%) Kimura. Warshaw was more commonly performed for larger tumors (2.5 cm vs. 1.5 cm, P <0.001), proximal lesions (specimen 8.2 cm vs. 5.7 cm, P <0.001), and malignant or complex disease , Kimura was more commonly performed minimally invasively (MIS) (73.1% vs. 44.1%, P <0.001) and was associated with shorter operative time. Higher ASA class, larger tumor size, pancreatic ductal adenocarcinoma, and the Warshaw technique independently predicted longer operative time in MIS cases, suggesting a preferential adoption of the Warshaw technique for technically more challenging tumor dissections. Short-term morbidity , readmission, and mortality rates were comparable. With a median follow-up of 85.8 monthssplenic hypoperfusion (30.4% vs. 12.2%, P =0.010), and perigastric varices (19.6% vs. 7.3%, P =0.056) were more frequent after Warshaw, although most were clinically silent, and the need for secondary splenectomy was rare (1.2%). Conclusions: Both techniques are safe and effective for SPDP. Warshaw is preferred for proximal, malignant, or complex lesions, while Kimura may minimize long-term splenic sequelae in small, distal, benign tumors. An anatomy- and disease -driven approach remains essential to optimize outcomes.

1 August 2024
Verified
Other
Open access
Marco VentinMarco Ventin
Marco Ventin
GCGiulia Cattaneo
Giulia Cattaneo
SAShahrzad Arya
Shahrzad Arya
JJJingyu Jia
Jingyu Jia
MGMaria Chiara Gelmi
Maria Chiara Gelmi
CFCristina R. Ferrone
Cristina R. Ferrone
Supplementary Table S2. Score of B7-H3 expression and clinical information of metastatic UM tissue samples.

1 August 2024
Verified
Other
Open access
Marco VentinMarco Ventin
Marco Ventin
GCGiulia Cattaneo
Giulia Cattaneo
SAShahrzad Arya
Shahrzad Arya
JJJingyu Jia
Jingyu Jia
MGMaria Chiara Gelmi
Maria Chiara Gelmi
CFCristina R. Ferrone
Cristina R. Ferrone
Supplementary Table S4. Correlation between clinicopathological characteristics of patients with primary ocular UM tumors from the TCGA cohort and B7-H3 mRNA expression.

1 August 2024
Verified
Other
Open access
Marco VentinMarco Ventin
Marco Ventin
GCGiulia Cattaneo
Giulia Cattaneo
SAShahrzad Arya
Shahrzad Arya
JJJingyu Jia
Jingyu Jia
MGMaria Chiara Gelmi
Maria Chiara Gelmi
CFCristina R. Ferrone
Cristina R. Ferrone
Supplementary Figure S1. Association between B7-H3 mRNA expression and overall survival in patients with UM.

1 August 2024
Verified
Other
Open access
Marco VentinMarco Ventin
Marco Ventin
GCGiulia Cattaneo
Giulia Cattaneo
SAShahrzad Arya
Shahrzad Arya
JJJingyu Jia
Jingyu Jia
MGMaria Chiara Gelmi
Maria Chiara Gelmi
CFCristina R. Ferrone
Cristina R. Ferrone
Supplementary Table S1. Score of B7-H3 expression of treatment-naïve primary UM tumor samples.